EBV–Associated Lymphoproliferative Disorders: Update in Classification
Abstract
Although about 90% of the world's population is infected by EBV only a small subset of the related infections result in neoplastic transformation. EBV is a versatile oncogenic agent involved in a multitude of hematopoietic, epithelial, and mesenchymal neoplasms, but the precise role of EBV in the pathogenesis of many of the associated lymphoid/histiocytic proliferations remains hypothetical or not completely understood. Additional studies and use of evolving technologies such as high-throughput next-generation sequencing may help address this knowledge gap and may lead to enhanced diagnostic assessment and the development of potential therapeutic interventions.
Publication Title
Surgical Pathology Clinics
Recommended Citation
Rezk, S., & Weiss, L. (2019). EBV–Associated Lymphoproliferative Disorders: Update in Classification. Surgical Pathology Clinics, 12 (3), 745-770. https://doi.org/10.1016/j.path.2019.03.002
